Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yoshinobu Mifune

Undersea and Hyperbaric Medicine Murrieta, CA Medical Doctor

NPI 1902896525 CMS profile 359321

28078 Baxter Rd, Suite 410, Murrieta, CA 92563

Open in the dashboard

General payments

$1,862

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yoshinobu Mifune of Murrieta, CA is reported in the CMS Open Payments database as having received $1,862 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $403 15
2024 General $240 10
2023 General $87 3
2022 General $180 8
2021 General $292 12
2020 General $168 9
2019 General $492 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yoshinobu Mifune
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Yoshinobu Mifune were reported at $403. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Yoshinobu Mifune Undersea and Hyperbaric Medicine median Middle half National median
2019 $492 $201 $85–$538 $163
2020 $168 $84 $31–$222 $114
2021 $292 $138 $52–$383 $132
2022 $180 $135 $51–$385 $149
2023 $87 $143 $75–$442 $160
2024 $240 $178 $80–$442 $164
2025 $403 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $539 23 payments
  2. Organogenesis Inc. $285 11 payments
  3. Smith+Nephew, Inc. $258 13 payments
  4. Kerecis Limited $178 5 payments
  5. AbbVie, Inc. $114 6 payments
  6. Derma Sciences, Inc. $109 1 payment
  7. Paratek Pharmaceuticals, Inc. $92 4 payments
  8. Amniox Medical, Inc. $44 3 payments
  9. Reapplix Inc. $36 1 payment
  10. Tactile Systems Technology Inc $32 2 payments
  11. Other $175 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,862 78 payments
Products named General payments · program years 2019–2025
  1. MEDIHONEY $360 11 payments
  2. AMNIOEXCEL $251 10 payments
  3. PRIMATRIX Recon-Skin And Wound $251 10 payments
  4. OMNIGRAFT $251 10 payments
  5. TCC-EZ $251 10 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $234 10 payments
  7. PRIMATRIX Recon-Skin And Wound $234 10 payments
  8. Integra Recon-Skin And Wound $146 7 payments
  9. Integra Recon-Skin And Wound $146 7 payments
  10. Integra Recon-Skin And Wound $146 7 payments
  11. Other $2,802 99 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

411

Median for Family Practice: 1,826

Drug cost

$53,183

Median for Family Practice: $120,094

Branded share of claims

26.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 76 $50,626
Mupirocin Generic 176 $1,363
Triamcinolone Acetonide Generic 70 $391
Doxycycline Hyclate Generic 37 $346
Ciprofloxacin Hcl Generic 19 $231
Ssd Silver Sulfadiazine Brand 13 $158
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 20 $67

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$190,515

Medicare's payments for the services billed

Medicare patients

273

Average age 74

Services billed

3,717

122 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 57%
Ischemic heart disease 47%
Heart failure 44%
Chronic kidney disease 42%
Atrial fibrillation 37%
Depression 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record